57 completed, 17 unknown, 12 terminated, 6 active not recruiting. 99 Phase 3, 14 Phase 2.
Follow Sorafenib: new trials by email Literature Review of Sorafenib trials Research Report on Sorafenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma BGB-B2033, Lenvatinib, Sorafenib - Hepatocellular Carcinoma, Liver Cancer | Phase 3 | Not yet recruiting | BeOne Medicines | 492 | 2026-10-01 | 2026-09-23 |
| MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib Gilteritinib, Sorafenib - Acute Myeloid Leukemia (AML), FLT3-ITD Mutation | Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | 594 | 2026-05-01 | 2026-03-20 |
| Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study Sorafenib (SORA), Venetoclax (VEN) - Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD) | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 87 | 2025-12-01 | 2025-12-04 |
| Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation Decitabine, Sorafenib (BAY-43-9006)，giritinib, Avastinib - AML, MDS | Phase 2 / Phase 3 | Recruiting | Ruijin Hospital | 126 | 2025-06-10 | 2025-05-18 |
| Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients Experimental: Venetoclax in combination with Decitabine (+-sorafenib), Active Comparator: Standard dose of Venetoclax + Azacitidine - Elderly AML Patients, Unfit, New-diagnosis AML | Phase 3 | Completed | The Second Affiliated Hospital of Kunming Medical University | 154 | 2023-11-01 | 2026-09-09 |
| Immunotherapy for Advanced Liver Cancer AlloStim® immunotherapy, FOLFOX regimen, Sorafenib - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Suspended | Mirror Biologics, Inc. | 150 | 2023-08-01 | 2025-10-23 |
| A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC HLX10, HLX04, Sorafenib - Hepatocellular Carcinoma (HCC) | Phase 3 | Withdrawn | Shanghai Henlius Biotech | 2022-11-15 | 2022-05-05 | |
| Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children Cladribine, G-CSF, Cytarabine - Leukemia, Monocytic, Acute, Pediatric AML | Phase 2 / Phase 3 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 43 | 2021-12-01 | 2023-07-27 |
| A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) camrelizumab；Rivoceranib, Rivoceranib, Sorafenib - Advanced Hepatocellular Carcinoma (HCC) | Phase 3 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 1 | 2021-09-26 | 2022-09-01 |
| A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab Atezolizumab, Lenvatinib, Sorafenib - Unresectable Hepatocellular Carcinoma | Phase 3 | Active not recruiting | Hoffmann-La Roche | 557 | 2021-04-26 | 2026-08-25 |
| Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT Radiotherapy plus Toripalimab, Sorafenib - Radiotherapy, Toripalimab | Phase 3 | Terminated | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 36 | 2021-03-02 | 2025-02-26 |
| A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC IBI310, Sintilimab, Sorafenib - Hepatocellular Carcinoma | Phase 3 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 344 | 2021-02-07 | 2026-03-19 |
| DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma DEB-TACE plus Sorafenib, DEB-TACE plus Lenvatinib, DEB-TACE plus PD-1 inhibitor - Hepatocellular Carcinoma | Phase 3 | Unknown | Guangxi Medical University | 90 | 2021-02-02 | 2021-02-09 |
| Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia Sorafenib - Acute Leukemia, Relapse | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 346 | 2020-12-15 | 2021-11-08 |
| SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma SCT-I10A, SCT510, Sorafenib 200mg - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Unknown | Sinocelltech Ltd. | 405 | 2020-11-11 | 2024-02-01 |
| Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC Toripalimab combined with Bevacizumab, Sorafenib - Advanced Hepatocellular Carcinoma (HCC) | Phase 3 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 326 | 2020-10-15 | 2026-07-13 |
| A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets - Advanced Hepatocellular Carcinoma (HCC) | Phase 3 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 648 | 2020-08-11 | 2025-02-20 |
| SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT SBRT+TACE+Sorafenib, Sorafenib - Unresectable Hepatocellular Carcinoma, Portal Vein Thrombosis | Phase 3 | Unknown | First Affiliated Hospital of Zhejiang University | 54 | 2020-04-30 | 2023-02-16 |
| Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer PD-1, Sorafenib - Advanced Liver Cancer | Phase 3 | Unknown | Guangxi Medical University | 50 | 2019-12-01 | 2019-11-14 |
| A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Nivolumab, Ipilimumab, Sorafenib - Hepatocellular Carcinoma | Phase 3 | Completed | Bristol-Myers Squibb | 732 | 2019-09-30 | 2026-08-25 |
Showing 20 of 99. Sign in to see all of them.
Carcinoma, Hepatocellular (51) · Carcinoma, Renal Cell (12) · Liver Neoplasms (12) · Neoplasms (11) · Carcinoma (5) · Leukemia, Myeloid, Acute (5) · Carcinoma, Non-Small-Cell Lung (4) · Neoplasm Metastasis (4) · Kidney Neoplasms (3) · Hepatoblastoma (2) · Melanoma (2) · Recurrence (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Desmoid Tumors (1)
Bayer (17) · Sun Yat-sen University (9) · National Cancer Institute (NCI) (6) · Pfizer (4) · AVEO Pharmaceuticals, Inc. (3) · Bristol-Myers Squibb (3) · Guangxi Medical University (3) · Nanfang Hospital, Southern Medical University (3) · Boston Scientific Corporation (2) · Hoffmann-La Roche (2) · Innovent Biologics (Suzhou) Co. Ltd. (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Abbott (1) · Ain Shams University (1) · Air Force Military Medical University, China (1)
China (58) · United States (41) · France (36) · Canada (34) · Italy (32) · United Kingdom (32) · Germany (31) · Spain (29) · South Korea (27) · Australia (24) · Belgium (24) · Poland (24) · Taiwan (24) · Russia (23) · Japan (18)
Ming Shi, MD (4) · Shukui Qin, MD (3) · Qifa Liu (2) · Robert J. Motzer, MD (2) · AbdelRahman Elnaggar, Prof. (1) · Al B Benson (1) · Anastasia Becker (1) · Antonio Gasbarrini, M.D. (1) · Bruno Daniele, M.D. (1) · Ciro Gallo, M.D., Ph.D (1)
PMID 27238653, PMID 28410911, PMID 37146227, PMID 28687477, PMID 34052255, PMID 35484400, PMID 36111952, PMID 37526095, PMID 11981766, PMID 12049862, PMID 12540794, PMID 16965911, PMID 17189398, PMID 17215530, PMID 17551296, PMID 18650514, PMID 18840822, PMID 19095497, PMID 19242495, PMID 19349552, PMID 19451442, PMID 19757215, PMID 19806596, PMID 19850637, PMID 20082451, PMID 20085939, PMID 20203173, PMID 20212250, PMID 20399677, PMID 20651059, PMID 20686792, PMID 20724077, PMID 20839057, PMID 21514523, PMID 21664811, PMID 21834960, PMID 21858552, PMID 22056247, PMID 22212936, PMID 22240282, PMID 22851564, PMID 23231599, PMID 23248256, PMID 23316013, PMID 23331661, PMID 23397536, PMID 23579211, PMID 23598172, PMID 23630366, PMID 23876062
2008 (4), 2009 (4), 2005 (3), U10CA021115 (3), U10CA180820 (3), 2017 (2), U10CA031946 (2), U10CA180821 (2), U10CA180886 (2), 2004 (1), 2016 (1), U10CA021661 (1), U10CA098543 (1)